Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hooton

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|January 6, 1999
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study TeamD M Parenti, P L Williams, R Hafner, et al.
The New England Journal of Medicine|December 24, 1998
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials GroupW M El-Sadr, R L Murphy, T M Yurik, et al.
American Journal of Epidemiology|September 18, 1999
Risk factors for HIV-1 shedding in semenC E Speck, R W Coombs, L A Koutsky, et al.
Science Translational Medicine|March 24, 2017
Bacterial virulence phenotypes of <i>Escherichia coli</i> and host susceptibility determine risk for urinary tract infectionsHenry L Schreiber, Matt S Conover, Wen-Chi Chou, et al.
The Journal of Infectious Diseases|June 3, 1999
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials GroupJ M Jacobson, J Spritzler, L Fox, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 12, 2019
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of AmericaLindsay E Nicolle, Kalpana Gupta, Suzanne F Bradley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2019
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of AmericaLindsay E Nicolle, Kalpana Gupta, Suzanne F Bradley, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approachSwaine L Chen, Chia-Seui Hung, Jian Xu, et al.
Ebiomedicine|July 1, 2015
Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent CystitisThomas J Hannan, Pacita L Roberts, Terrence E Riehl, et al.
The Journal of Urology|December 31, 2017
A Case-Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research NetworkSiobhan Sutcliffe, Thomas Jemielita, H Henry Lai, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|January 6, 1999
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study TeamD M Parenti, P L Williams, R Hafner, et al.
The New England Journal of Medicine|December 24, 1998
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials GroupW M El-Sadr, R L Murphy, T M Yurik, et al.
American Journal of Epidemiology|September 18, 1999
Risk factors for HIV-1 shedding in semenC E Speck, R W Coombs, L A Koutsky, et al.
Science Translational Medicine|March 24, 2017
Bacterial virulence phenotypes of <i>Escherichia coli</i> and host susceptibility determine risk for urinary tract infectionsHenry L Schreiber, Matt S Conover, Wen-Chi Chou, et al.
The Journal of Infectious Diseases|June 3, 1999
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials GroupJ M Jacobson, J Spritzler, L Fox, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 12, 2019
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of AmericaLindsay E Nicolle, Kalpana Gupta, Suzanne F Bradley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2019
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of AmericaLindsay E Nicolle, Kalpana Gupta, Suzanne F Bradley, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approachSwaine L Chen, Chia-Seui Hung, Jian Xu, et al.
Ebiomedicine|July 1, 2015
Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent CystitisThomas J Hannan, Pacita L Roberts, Terrence E Riehl, et al.
The Journal of Urology|December 31, 2017
A Case-Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research NetworkSiobhan Sutcliffe, Thomas Jemielita, H Henry Lai, et al.
Pageof 17